Loading clinical trials...
Loading clinical trials...
This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabet...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novo Nordisk A/S
NCT05398783 · Metabolic Disorders, Cancer, and more
NCT07224321 · Type 1 Diabetes Mellitus
NCT07395050 · Stage 3 Type 1 Diabetes
NCT01399385 · Healthy, Obesity, and more
NCT07340320 · Type II Diabetes Mellitus
Novo Nordisk Investigational Site
Fresno, California
Novo Nordisk Investigational Site
Fort Lauderdale, Florida
Novo Nordisk Investigational Site
Gurnee, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions